◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound SKIP-FOR-NOW HIGH

rHGH (Recombinant Human Growth Hormone)

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict SKIP-FOR-NOW HIGH

"For this archetype (20yo, peak endogenous GH/IGF-1 axis, MMA athlete, business owner, brain-priority, lean-mass not the bottleneck) — pharmaceutical rHGH on a peak-functioning natural axis is the single clearest \"wrong drug, wrong patient\" call in the entire GH-axis class. Direct GHR agonism bypasses every feedback loop the GHRH analogs and secretagogues at least partially preserve; supraphysiologic IGF-1 elevation is essentially guaranteed at any meaningful dose (even 1-2 IU/day clinic protocol pushes IGF-1 above age-normal in healthy young adults). All the same mechanistic concerns that drive SKIP-AT-20 for sermorelin/CJC-1295/MK-677 (peak natural baseline, late-adolescent neurodevelopment, fluid retention worsening cubital tunnel, no demonstrated benefit for combat-athlete bottlenecks) apply with **greater magnitude** because rHGH produces a larger and more sustained GH/IGF-1 surge than any upstream secretagogue. Plus: the long-term safety record of supraphysiologic GH exposure in healthy adults is the worst in the GH-axis class — Liu 2007 Annals meta-analysis (31 RCTs, 220 participants over 27 years) documented significant increase in adverse events (edema 44%, arthralgia 28%, CTS 24%, gynecomastia 18%, glucose intolerance 8%) without clinically meaningful body-comp benefit. The Rudman 1990 NEJM paper that birthed the entire anti-aging-clinic industry was n=12 over 6 months, never showed mortality or longevity benefit. rHGH is unambiguously criminalized for off-label distribution under 21 USC § 333(e) — unique among Rx drugs. Counterfeit gray-market product (\"blue tops\", \"red tops\", \"Hygetropin\", \"Kigtropin\") frequently underdosed (50-90% of label) or substituted with HGH-fragment 176-191. The lean-mass concept doesn't address combat-athlete bottlenecks (sleep, cervical injury, weight management, mental health, nervous-system fatigue all higher leverage). The ONLY archetypes where rHGH is appropriate are (a) documented adult or pediatric GH deficiency on stim test (insulin tolerance test gold standard, glucagon stim alternative, GHRH+arginine alternative) under endocrinology supervision — STRONG-CANDIDATE; (b) HIV wasting / cachexia (FDA-approved Serostim); (c) other FDA-approved indications. **Higher confidence than CJC-1295 (MEDIUM) or MK-677 (MEDIUM-HIGH)** because rHGH's evidence base is unambiguous, the magnitude differential is clear, and the legal/regulatory exposure is the largest in the class. Would NOT change verdict at 30+ unless documented adult-onset GH deficiency on stim test — sermorelin / tesamorelin / CJC + ipamorelin remain better risk/reward for general age-related GH decline; rHGH belongs reserved for genuine deficiency or specific FDA-approved indications."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, high cognitive workload, athletic, MMA / weight-managed combat sport (this-archetype)
    SKIP-AT-

    (HIGH confidence). The single most decisive skip in the GH-axis class. Peak natural GH/IGF-1 at lifetime peak; direct GHR agonism bypasses all feedback loops; supraphysiologic IGF-1 essentially guaranteed; brain-development concern (PFC maturation continues into mid-20s); fluid retention worsens cubital tunnel; no evidence base for benefit in healthy young adults; criminalized off-label distribution; WADA banned. Higher confidence than CJC-1295 (MEDIUM), MK-677 (MEDIUM-HIGH), or sermorelin (MEDIUM-HIGH) because rHGH is the bluntest tool, has the worst risk/reward at peak baseline, and the evidence base for healthy non-deficient adult use (Liu 2007) is unambiguous about modest benefit and significant adverse events.

  • 20-30, sedentary or non-weight-managed, healthy with peak natural GH/IGF-1
    SKIP-AT-

    (HIGH confidence). Same logic minus weight-management collision.

  • 20-30 with documented pediatric or adult GH deficiency on stim test
    STRONG-CANDIDATE

    (HIGH confidence) UNDER ENDOCRINOLOGY SUPERVISION. Genuine deficiency is a real medical indication. rHGH replacement at 0.2-0.6 mg/day SC daily, titrated to IGF-1 in upper half of age-appropriate normal range, is standard of care.

  • 30-50, executive maintenance, normal IGF-1
    SKIP

    No evidence base for benefit; Liu 2007 picture generalizes. Sermorelin, tesamorelin, CJC + ipamorelin are far better risk/reward.

  • 30-50, declining IGF-1 documented, recovery / body comp problem
    SKIP

    for rHGH; CONSIDER UPSTREAM SECRETAGOGUES. Direct rHGH reserved for documented deficiency on stim test, not for "low-normal IGF-1."

  • 30-50, documented adult-onset GH deficiency on stim test
    STRONG-CANDIDATE

    (HIGH confidence) UNDER ENDOCRINOLOGY SUPERVISION.

  • 50+, mild cognitive decline, normal IGF-1
    SKIP

    for rHGH; CONSIDER LIFESTYLE / OTHER.

  • 50+, sarcopenia, declining IGF-1, recovery decline, anti-aging-clinic context
    WATCH-LIST

    for rHGH (LOW-MEDIUM confidence at 1-2 IU/day clinic doses); SECRETAGOGUES PREFERRED.

  • 50+ with documented adult GH deficiency on stim test
    STRONG-CANDIDATE

    (HIGH confidence) UNDER ENDOCRINOLOGY SUPERVISION.

  • HIV wasting / cachexia (FDA-approved indication)
    STRONG-CANDIDATE

    (FDA-approved). Serostim at 0.1 mg/kg/day for 12 weeks.

  • Pediatric GHD, Turner, Prader-Willi, ISS, SHOX, SGA, Noonan, CKD-related growth failure (FDA-approved)
    PRIMARY-PICK

    / STRONG-CANDIDATE (FDA-approved). Pediatric endocrinology context.

  • Anxiety-prone
    NEUTRAL
  • High athletic load, tested status (any combat sport, endurance, strength competing under WADA / USADA / NCAA)
    WADA S

    1 banned in/out-of-competition. Detection: isoform-ratio test (24-48hr); biomarker test (IGF-1 + P-III-NP, ~2-3 weeks). Both operational since 2010s.

  • High athletic load, untested status (the user profile)
    SKIP-AT-

    WADA-irrelevant due to untested status, but the medical case at 20 with peak baseline is decisively against.

  • Sleep-disordered
    NEUTRAL

    Slow-wave sleep enhancement reported but small.

  • Recovery-focused (post-injury, post-illness, post-surgery in adults)
    WATCH-LIST

    (LOW-MEDIUM) for serious post-trauma cases. BPC-157 and TB-500 more evidence-supported peptide options.

  • Strength/anabolic-focused, bulking phase, competitive bodybuilding context
    WATCH-LIST

    Cosmetic doses produce real body-comp changes but at the cost of significant adverse events, criminalized distribution, WADA banned, and chronic high-dose use produces irreversible acromegaloid changes. Testosterone replacement is much better risk/reward.

  • Cancer cachexia / clinical cachexia
    NOT FIRST LINE

    Anamorelin, megestrol, or ghrelin-pathway agonists generally preferred.

  • Older with declining recovery, post-sport-career
    SECRETAGOGUES

    > rHGH.

  • Documented post-pituitary-surgery or post-radiation GHD
    STRONG-CANDIDATE

    (FDA-approved).

▸ Subjective experience (deep)

Compiled from published trials, bodybuilding-forum aggregated reports, anti-aging-clinic patient outcome data, and adult GHD replacement clinical experience.

First 1-7 days:

  • Often no acute "feel" — rHGH is silent on injection, no flushing, no warmth, no ghrelin-receptor-style hunger surge.
  • Subtle fatigue or mild headache in some users for first 1-3 days as IGF-1 rises.
  • Slight peripheral fluid retention — puffiness in fingers, around eyes, ankles.
  • Improved sleep depth — slower onset than ipamorelin / MK-677, emerging over week 2-3.

Weeks 1-4:

  • Edema / fluid retention 2-5 lb water weight — peripheral, sometimes facial. Most pronounced 2-6 weeks.
  • Tingling / numbness in fingers — paresthesia from fluid retention compressing nerves. Worse with rHGH than with upstream secretagogues at equivalent IGF-1.
  • Joint stiffness or arthralgia — fluid in joint capsules + direct GH effect on synovium.
  • Sleep depth often improves — slow-wave sleep enhancement, vivid dreams. Most consistent positive subjective effect.
  • Body composition begins shifting — visible visceral fat loss by week 3-4.
  • Mild fasting glucose elevation — measurable on bloodwork (5-15 mg/dL).
  • Skin thickness / hydration improvement — slow, modest.

Weeks 4-12:

  • Body composition shifts stabilize; body fat down 1-3% in non-trained users at typical replacement; more at higher doses.
  • Edema may partially resolve as kidneys adapt; usually some residual.
  • HbA1c trends upward in some (~0.1-0.3 over 6 months).
  • CTS-like symptoms emerge in 5-25% of users (higher dose, higher rate).
  • Energy / well-being improvements in genuine GHD-replaced users; less clear in non-deficient users.

Months 3-12 (long-term users):

  • Body composition plateaus.
  • Persistent moderate edema in many; subset develop chronic CTS.
  • HbA1c trend continues up in some — long-term metabolic concern.
  • Bodybuilding high-dose users (4-10 IU/day chronic): acromegaloid changes begin emerging — facial coarsening, jaw growth, hand/foot enlargement, organomegaly ("HGH gut"), tooth spacing. Bone changes essentially permanent.
  • CV signals may emerge: rising RHR, mild BP elevation, eventually echocardiographic LV wall thickening.
  • Glucose handling progressively worsens in genetically susceptible users.

Compared to upstream GH-axis compounds:

  • Faster onset, larger magnitude, more intense than sermorelin / CJC-1295 / ipamorelin / MK-677 at equivalent IGF-1.
  • No pulsatile mimicry — sustained / supraphysiologic exposure.
  • Higher edema, CTS, glucose, joint adverse-event rates.
  • No appetite drive (ipamorelin and MK-677 raise appetite; rHGH does not).

Variability is high. Subjective benefits in non-deficient healthy users are easy to confuse with placebo + sleep architecture changes + body-comp diet/training discipline correlated with starting the drug. Genuine GHD replacement subjective experience is qualitatively different from non-deficient cosmetic use.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: GHR generally not significantly desensitized at therapeutic / replacement doses; receptor downregulation described at sustained supraphysiologic exposure. Adult GHD patients on lifelong replacement do not show progressive tachyphylaxis.
  • Recommended cycle (adult GHD replacement): Continuous and lifelong.
  • Recommended cycle (anti-aging / bodybuilding off-label): Variable. Continuous for 6-24 months with periodic IGF-1 monitoring is common. Some 3 months on / 1 month off. No empirical basis — borrowed from anabolic-steroid cycling logic.
  • Reset protocol: Stopping daily somatropin clears rapidly (5 half-lives ≈ 12-24 hours); long-acting clears in 5-7 days. IGF-1 returns to baseline over 1-3 weeks. Edema clears 1-3 weeks. Body composition reverts toward baseline over months unless training/diet maintain.
▸ Stacking deep dive

Synergistic with

  • Resistance training + adequate protein intake: GH/IGF-1 elevation produces body composition change only with anabolic stimulus + amino acid availability.
  • Adequate sleep: GH endogenously released primarily during slow-wave sleep. Optimizing sleep upstream amplifies endogenous pulses.
  • IGF-1 LR3 / mecasermin (theoretical): Direct downstream IGF-1. Bodybuilding-community combo. Synergistic but adverse-event burden compounds.
  • Insulin (bodybuilding combo, dangerous): rHGH antagonizes insulin → exogenous insulin counters diabetogenic effect + adds anabolic insulin signaling. Mechanistically rational; safety nightmare; multiple deaths in bodybuilding community.
  • Testosterone replacement / anabolic steroids: Synergistic anabolic effect; commonly stacked. Combined adverse event burden compounds.
  • Hyperthyroid (T3 / T4): Bodybuilding use. Increases metabolic rate, amplifies lipolysis. CV / arrhythmia risk.
  • GLP-1 agonists (semaglutide, tirzepatide): Offset rHGH-induced glucose intolerance while supporting visceral fat loss. Increasingly stacked.

Avoid stacking with

  • GHRH analogs (sermorelin, CJC-1295, tesamorelin): Mechanistically nonsensical. Exogenous rHGH suppresses pituitary GH release via IGF-1 feedback; GHRH analog action muted.
  • GH secretagogues (ipamorelin, GHRP-2/6, MK-677): Same logic. Endogenous GH release suppressed by exogenous rHGH.
  • Glucocorticoids / chronic prednisone: Steroid-induced + rHGH-induced insulin resistance compound multiplicatively. Glycemic catastrophe risk.
  • High-dose oral estrogen: Suppresses hepatic IGF-1 generation; partly counteracts rHGH's IGF-1-mediated anabolic effects. Transdermal estrogen has less effect.

Neutral / safe co-administration

  • Most CNS nootropics (modafinil, racetams, citicoline)
  • Standard supplement stacks (V4-style — Mg, fish oil, NAC)
  • Most antihypertensives
  • Statins, metformin (no significant interaction)
  • Selegiline, bupropion, modafinil
▸ Drug interactions deep dive
  • No significant CYP induction/inhibition — protein drug, not metabolized via hepatic CYP.
  • Insulin / oral antidiabetics: rHGH is insulin-antagonistic; diabetic patients on insulin or sulfonylureas may need substantial dose adjustment. Most clinically important interaction.
  • Glucocorticoids: Additive insulin resistance; pharmacodynamic antagonism. Adult GHD patients on glucocorticoid replacement need lower hydrocortisone dose (rHGH increases 11β-HSD1 activity).
  • Levothyroxine / thyroid hormone: rHGH alters T4→T3 conversion (increases). Hypothyroid patients on stable T4 may need dose reduction; new-onset subclinical hypothyroidism may emerge.
  • Estrogen (oral): Suppresses hepatic IGF-1 generation; oral estrogen-replaced women need higher rHGH doses. Transdermal estrogen does not.
  • Hormonal contraceptives: No CYP3A4 interaction; oral estrogen effect on IGF-1 still applies.
  • Anticoagulants: No direct interaction; injection-site bruising on warfarin/DOAC, monitor.
▸ Pharmacogenomics
  • GHR exon 3 deletion polymorphism (d3-GHR): ~25-50% population frequency; carriers have enhanced GHR signaling and may show greater IGF-1 response. Most clinically relevant PGx variant for rHGH dosing. Pediatric GHD patients with d3-GHR achieve greater height gain at equivalent doses; adult GHD shows greater IGF-1 response. Trackable on 23andMe with manual analysis.
  • IGF1 SNPs (rs7136446, rs5742612, rs35767, rs1520220): Modulate baseline IGF-1; carriers of low-IGF-1 alleles may show larger relative response.
  • IGFBP-3 promoter polymorphisms: Affect bioavailability of free vs. bound IGF-1.
  • GHRHR variants: Less relevant for rHGH (which bypasses GHRHR) than for GHRH analogs.
  • IGF-1R variants: Some long-lived human centenarian populations show enrichment of IGF-1R loss-of-function variants.
  • Practical takeaway: No actionable PGx for off-label rHGH dosing decisions in 2026. For genuine GHD replacement, d3-GHR may modestly inform titration but is not standard of care.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (FDA-approved daily brand) Genotropin (Pfizer), Humatrope (Eli Lilly), Norditropin (Novo Nordisk), Saizen (EMD Serono), Omnitrope (Sandoz biosimilar), Nutropin (Genentech), Zomacton (Ferring), Serostim (EMD Serono — HIV wasting) $1,500-3,000/month brand at adult GHD replacement; up to $10,000+/month at cosmetic doses. Insurance covers FDA-approved indications. Highest Endocrinologist-confirmed GHD diagnosis required (insulin tolerance test gold standard, glucagon stim alternative, GHRH+arginine alternative). Off-label distribution criminalized under 21 USC § 333(e).
US Rx (long-acting weekly) Sogroya (somapacitan, Novo Nordisk — adult AND pediatric), Skytrofa (lonapegsomatropin, Ascendis — pediatric), Ngenla (somatrogon, Pfizer — pediatric) $30,000-60,000/year Highest Once-weekly SC. Better compliance. Off-label more limited than daily somatropin.
US Rx (biosimilar) Omnitrope (Sandoz); additional biosimilars in pipeline $1,000-2,500/month High FDA-approved biosimilars. Same molecule, lower cost. Standard endocrinology preference for cost-conscious care.
Telehealth / anti-aging clinic Rx Defy Medical, Hone Health, Marek Health, etc. $400-1,500/month at 1-2 IU/day Variable; clean source through compounding-pharmacy or licensed-distributor channel Diagnosis often based on low-normal IGF-1 rather than full stim test. Legally tenuous prescription path; medically not ideal first line for general "low IGF-1" without confirmed deficiency.
Gray market — China-sourced "generic" hGH Hygetropin, Jintropin (Chinese-licensed), Kigtropin, ZPHC, "blue tops", "red tops", "green tops" $200-400/month at 4-10 IU/day cosmetic Variable to LOW. Counterfeit common. Some vendors deliver real product (Jintropin from GeneScience); others underdosed, contaminated, or substituted with HGH-fragment 176-191. Bodybuilding-community gray market. Real products and counterfeits coexist. Independent serum GH peak testing post-injection is the verification standard. Quality is genuinely unpredictable.
Gray market — Iranian "generic" Cinnatropin (CinnaGen) $200-400/month Medium Iranian biotech industry produces real recombinant products; export channels variable. Often more reliable per-batch than China-gray-market but supply-chain interruption-prone.
Gray market — Russian / Eastern European Various $200-400/month Variable Per-batch variable; vendor reputation overall mixed.
Compounding pharmacy Generally not available n/a n/a Somatropin is a complex biologic, not compoundable in 503A context. CJC-1295 / tesamorelin compounding-pharmacy story does not apply to rHGH.

Quality concerns with gray-market: rHGH is a complex 191-amino-acid biologic protein. QC requires bioassay, mass spectrometry, ideally in-vivo bioactivity testing. Independent gray-market analyses 2018-2026 have found:

  • Some genuine product (Jintropin from GeneScience, Cinnatropin from CinnaGen) at full label content
  • Many underdosed batches (50-90% of label claim — sometimes degradation, sometimes intentional dilution)
  • Counterfeit products containing little or no rHGH
  • Substitution with HGH-fragment 176-191 — a much shorter peptide that is cheap to synthesize and has none of the full hGH systemic effects (only retains a debated fat-loss mechanism via beta-3 adrenergic receptors). Very common counterfeit pattern in "blue tops" / "red tops"
  • Bacterial contamination in some batches (failed vial sterility)
  • Mislabeled "generic" product that is actually a different cytokine or hormone

Cost arbitrage gap is large. US brand at adult GHD replacement: ~$1,500-3,000/month. China-gray-market at cosmetic dose: ~$200-400/month. The 5-15× cost differential is real but the quality-variance differential is also real.

Legal risk in gray-market: Possession by an end user generally not federally prosecuted at small quantities. Distribution / importation criminalized. Customs seizures of bulk hGH shipments routine; individual user shipments occasionally seized. Federal prosecution of individual users for possession is rare; importing small quantities for "personal use" is in gray legal territory but enforced selectively.

Sourcing for users in this archetype: Not applicable — verdict is SKIP-AT-20. Cost is not the gating factor.

▸ Biomarkers to track (deep)

  • Baseline (before starting):

    • IGF-1, IGFBP-3 (primary efficacy + safety biomarkers; target upper half of age-appropriate normal range)
    • Stim test for documenting deficiency (insulin tolerance test gold standard, glucagon stim alternative, arginine + GHRH test alternative) — required before initiating replacement
    • Fasting glucose, fasting insulin, HOMA-IR, HbA1c (rHGH has the strongest A-tier glucose intolerance signal in the GH-axis class — track carefully)
    • Lipid panel (LDL, HDL, triglycerides, ApoB)
    • Prolactin, AM cortisol (baseline; pituitary-deficient patients may have multiple hormone deficiencies; replace cortisol BEFORE starting rHGH)
    • Free + total testosterone, LH, FSH, SHBG, estradiol (HPG-axis baseline)
    • TSH + free T4, free T3 (rHGH affects T4→T3 conversion)
    • ALT, AST, GGT (general hepatic baseline)
    • CBC, BMP (general health baseline)
    • Resting heart rate, blood pressure, body weight, waist circumference (edema baseline)
    • BNP / NT-proBNP (only if cardiac risk factors present)
    • Echocardiogram (baseline for chronic-use plans; LV mass, wall thickness, EF)
    • P-III-NP — WADA biomarker for athlete testing
    • Body composition (DXA scan baseline)
    • Cancer screening age-appropriate

  • During use (months 1, 3, 6, then quarterly):

    • IGF-1 every 6-8 weeks during titration; target upper-normal range, do NOT exceed +2 SDS
    • Fasting glucose, HbA1c quarterly
    • Lipid panel quarterly
    • Body weight, BP, HR weekly to monthly (edema watch)
    • Symptom log — paresthesia, joint pain, headaches, edema, glucose symptoms, sleep changes, vision changes
    • Body composition (DXA) at 6 and 12 months
    • Free T4, TSH annually
    • Echocardiogram annually for chronic high-dose / multi-year use
    • Cancer screening age-appropriate

  • Post-cycle (if cycled or discontinued):

    • IGF-1 2-4 weeks post-cessation to confirm return to baseline
    • Fasting glucose, HOMA-IR, HbA1c to confirm reversibility
    • Body weight + edema markers (typically 1-3 weeks)
    • Body composition to characterize reversion
▸ Controversies / open debates Live debate

1. The "rhgh" vs. "hgh" entry distinction on this wiki

Both entries refer to the same molecule (191-aa recombinant somatropin). The split is editorial: the "hgh" entry is the physiology-and-broader-context lens (mechanism, anti-aging history, Rudman-vs-Liu narrative); the "rhgh" entry is the pharmaceutical-product lens (brand list, FDA-approval timeline, sourcing/regulatory, gray-market quality, long-acting weekly variants). Cross-references between the two are intentional. Treat as a single compound for stacking and biomarker decisions — do not stack "rhgh" with "hgh".

2. Counterfeit gray-market product — "blue tops" / "red tops" reality

The bodybuilding gray market for "generic Chinese hGH" has operated since the 1990s. Genuine product (Jintropin from GeneScience, Cinnatropin from CinnaGen) coexists with extensive counterfeiting:

  • Underdosed batches at 50-90% label claim — sometimes from degradation in shipping, sometimes intentional dilution.
  • HGH-fragment 176-191 substitution — a much shorter peptide cheap to synthesize that has none of the full hGH systemic effects (retains debated beta-3 adrenergic fat-loss mechanism only). This is the dominant counterfeit pattern in "blue tops" sold for $200-400/month.
  • Outright fake product containing no GH or unrelated cytokines/hormones.
  • Bacterial contamination in some batches.

Independent serum GH peak testing post-injection is the verification standard among experienced gray-market users — a 1 IU SC dose should peak serum GH at 15-25 ng/mL within 2-4 hours; sub-5 ng/mL peaks indicate underdosed or counterfeit product. Most users do not test. The cost arbitrage (5-15× cheaper than US Rx) explains continued gray-market demand despite quality variance.

3. The Rudman 1990 NEJM paper — the founding study and its honest legacy

Rudman 1990 is THE foundational citation for anti-aging HGH use. It is also a 12-person, 6-month, three-times-weekly trial in older men with low-normal baseline IGF-1, with no longevity outcome, no functional outcome benefit, no cardiovascular outcome, and a "10-20 years of aging reversed" framing based entirely on body-composition and skin-thickness shifts at 6 months. The body-composition shifts were real (lean mass +8.8%, fat mass -14.4% vs. placebo in the 6-month window), but the extrapolation to "anti-aging" or "longevity" was Rudman's editorial framing, not his data.

Honest reading: Rudman 1990 demonstrated GH-axis pharmacology in a setting where it would predictably produce body-composition shifts. The paper did not establish anti-aging benefit or longevity benefit. The entire anti-aging-HGH industry built on Rudman's framing was a clinical reach that was subsequently punctured by the 2007 Liu meta-analysis but persists commercially because the body-composition signal is real and patient-perceptible.

4. The Liu 2007 Annals meta-analysis — the rebuttal and what it actually shows

Liu et al. 2007 systematically reviewed 31 RCTs of HGH in healthy adults over 27 years (220 participants total). Findings: small body-composition improvement (~2 kg fat loss, ~2 kg lean gain), no functional outcome benefit (strength, exercise capacity, BMD, cholesterol), and significantly increased adverse events (edema 44%, arthralgia 28%, CTS 24%, gynecomastia 18%, glucose intolerance 8%). The authors concluded: "these changes were not accompanied by other clinical benefits. Adverse effects were frequent."

Honest reading: The benefit is real but smaller than industry implies; the adverse events are significant; the longevity / functional outcome benefits do not exist in published RCT data. The risk/reward in healthy non-deficient adults is unfavorable.

5. The IGF-1 cancer signal — strongest in the GH-axis class

The IGF-1-cancer-axis hypothesis has multiple converging lines:

  • Acromegaly patients (chronic supraphysiologic GH/IGF-1): 2-4× increased colorectal cancer; modestly increased breast and prostate
  • Healthy adult epidemiology (Renehan 2004 Lancet): Upper-quartile IGF-1 with prostate, breast, colorectal cancer (modest hazard ratios)
  • Laron syndrome (Guevara-Aguirre 2011): Near-zero lifetime cancer
  • Long-lived dwarf mouse models: 30-50% increased lifespan with low GH/IGF-1
  • Pediatric GH replacement registries (KIGS, SAGhE): Modest second-neoplasm signal in childhood-cancer survivors; controversial; small absolute risk
  • Adult GHD replacement (KIMS 2022): No clear cancer signal at physiologic replacement

Honest reading: Cancer concern is real and stronger for rHGH than for any other GH-axis compound because rHGH produces the largest and most sustained IGF-1 elevation. At physiologic GHD replacement, cancer risk appears small. At chronic supraphysiologic doses for years, the risk model becomes more concerning. For a 20-year-old with peak natural IGF-1, exogenous rHGH would push IGF-1 firmly into supraphysiologic range — the worst possible window.

6. Acromegaloid changes at chronic high-dose use — visible and mostly irreversible

Acromegaloid changes (jaw growth, frontal bossing, hand/foot enlargement, organomegaly, "HGH gut" / "Palumboism") documented in chronic high-dose bodybuilding use over 5-10+ years. Bone changes essentially irreversible. Soft tissue partially reversible on discontinuation.

7. Federal criminalization of off-label distribution — 21 USC § 333(e)

rHGH is unique among prescription drugs in that off-label distribution is explicitly criminalized at the federal level. Up to 5 years imprisonment + fines (10 years if to a minor for athletic enhancement). The statute targets distributors, not end users — possession is generally not federally prosecuted. Prescribing rHGH for anti-aging or athletic enhancement creates legal exposure for the prescriber that does not exist for most other off-label drug use.

8. Long-acting weekly somatropin — convenience vs. pulsatility

Sogroya / Skytrofa / Ngenla replace daily somatropin with weekly SC. Improved compliance is real and meaningful. Mechanistic trade-off: weekly long-acting forms produce sustained GH elevation rather than daily pulses. Olsson 2024 LAGH1 Phase 3 demonstrated non-inferiority for height velocity in pediatric GHD; long-term comparative data is thin. Whether sustained vs. pulsatile exposure matters for endpoints other than IGF-1 elevation is incompletely characterized.

9. The "low-normal IGF-1 = GHD" framing in anti-aging clinics

Anti-aging clinics routinely diagnose "GH deficiency" based on low-normal baseline IGF-1 alone, without insulin tolerance test or glucagon stim test. This is not the FDA-approved diagnostic criterion for adult GHD. Genuine adult GHD requires demonstrating failed GH response to a stimulus. Low IGF-1 has many causes (oral estrogen, malnutrition, low GH but functioning axis, age-appropriate normal variation). The clinic-based "low IGF-1 = GHD" diagnosis is medically dubious and legally exposed under 21 USC § 333(e).

10. Why rHGH is the worst risk/reward in the GH-axis class for non-deficient users

For any goal (body comp, recovery, sleep, longevity) in a non-deficient adult, the GH-axis upstream secretagogues (sermorelin, tesamorelin, CJC-1295 + ipamorelin) preserve some pulsatility, produce smaller IGF-1 peaks, lower edema rate, lower CTS rate, lower glucose intolerance rate, lower cost, fewer legal issues. rHGH's only advantage over upstream secretagogues is magnitude — the IGF-1 peak is bigger, the body-comp effect is faster, the lipolysis is more direct. For someone with a genuine GH deficiency, this magnitude is what you want; for someone with peak natural axis, it's what makes the drug actively worse.

11. WADA detectability and athlete risk

rHGH is detectable via:

  • Isoform-ratio test (Bidlingmaier 2014) — distinguishes pituitary multi-isoform from recombinant single 22 kDa isoform; detection 24-48 hours post-injection
  • Biomarker test (IGF-1 + P-III-NP) — detects sustained downstream effect; ~2-3 weeks

Both tests operational in WADA-tested sports for over a decade. Disqualifying for any tested athlete.

12. The cost / access asymmetry

US Rx rHGH at adult GHD replacement: $1,500-3,000/month brand. Gray-market China-sourced cosmetic dose: $200-400/month. 5-15× cost differential. This asymmetry has driven the entire bodybuilding-community gray-market hGH economy since the 1990s.

▸ Verdict change log
  • 2026-05-10 — Initial verdict: SKIP-AT-20 (HIGH confidence) for users in this archetype-archetype. Rationale: at 20, peak endogenous GH/IGF-1 axis means direct exogenous GHR agonism produces supraphysiologic signaling that bypasses every protective feedback loop; chronic supraphysiologic IGF-1 during late-adolescent neurodevelopment is uncharacterized and theoretically concerning; rHGH produces the largest IGF-1 peaks and largest fluid-retention burden in the GH-axis class (worse for cubital tunnel than upstream compounds); Liu 2007 meta-analysis demonstrates modest body-comp shifts + significant adverse events without functional or longevity benefit in healthy non-deficient adults; Rudman 1990 founding study was a 12-person 6-month trial that never showed longevity benefit; cancer / IGF-1 oncology concern is strongest in the class for rHGH due to magnitude and sustainability of IGF-1 elevation; off-label distribution criminalized under 21 USC § 333(e); WADA banned; counterfeit gray-market product (blue tops / red tops) frequently underdosed or substituted with HGH-fragment 176-191. HIGH confidence (vs. MEDIUM for CJC-1295, MEDIUM-HIGH for sermorelin/MK-677) because rHGH's evidence base is unambiguous and the risk/reward at peak natural axis is the worst in the class. Verdict moves to STRONG-CANDIDATE (HIGH confidence) only with documented adult or pediatric GH deficiency on stim test under endocrinology supervision — genuine deficiency is a real medical indication; FDA-approved replacement is standard of care. For general age-related GH decline at 30+/50+, sermorelin / tesamorelin / CJC + ipamorelin are far better risk/reward than direct rHGH — would not switch verdict to anti-aging rHGH at any age without confirmed deficiency. The single most decisive SKIP in the GH-axis class for users in this archetype-archetype.
▸ Open questions / gaps Open
  1. No RCT of rHGH in healthy young adults (18-30) at any dose. Long-term safety/efficacy data in <30yo healthy users absent.
  2. No data on effect of chronic supraphysiologic IGF-1 during late-adolescent neurodevelopment. Brain development continues into mid-20s; precautionary argument is mechanistic rather than empirically established.
  3. Long-term oncology surveillance in healthy adults using off-label rHGH essentially absent. Acromegaly literature provides indirect evidence.
  4. Cardiac outcomes in healthy younger adults at chronic use. Acromegaly cardiomyopathy well-characterized; mini-acromegaly phenotype in chronic high-dose bodybuilders is case-series-supported but not RCT-quantified.
  5. Long-acting weekly somatropin in non-pediatric / non-GHD populations. Limited off-label use; long-term comparative data with daily somatropin thin.
  6. Combat-sport / weight-class athlete specific data. None.
  7. Optimal IGF-1 target for genuine GHD replacement — current consensus is upper half of age-appropriate normal range; whether genuinely optimal or simply conservative is debated.
  8. Whether modest exogenous rHGH in non-deficient older adults provides any longevity benefit — Liu 2007 picture says no functional / longevity benefit; positive case rests on Rudman 1990 framing rather than data.
  9. For the user specifically: The question that would re-open verdict is whether bloodwork at 30+/50+ documents adult-onset GH deficiency on insulin tolerance test or glucagon stim test (not just low-normal IGF-1). None of those conditions apply now or are likely within the next 10-15 years.

References

Liu H, Bravata DM, Olkin I, et al. 2007 — Systematic Review of GH for Healthy Adults (Ann Intern Med, PMID 17204199)

pubmed.ncbi.nlm.nih.gov · 2007

Definitive meta-analysis; modest body comp + significant adverse events + no functional benefit

View Study

Olsson DS, Bidlingmaier M, Maghnie M, et al. 2024 — LAGH1 Lonapegsomatropin (Skytrofa) Pediatric GHD Phase 3

pubmed.ncbi.nlm.nih.gov · 2024

Pivotal long-acting weekly somatropin trial supporting Skytrofa pediatric GHD approval

View Study

Sävendahl L, Maes M, Albertsson-Wikland K, et al. 2017 — SAGhE Long-Term Mortality / Safety in Childhood GH Treatment (PMID 28204394)

pubmed.ncbi.nlm.nih.gov · 2017

Multi-cohort European long-term safety

View Study

Bidlingmaier M, Friedrich N, Emeny RT, et al. 2014 — GH Detection Methods (Isoform-Ratio + Biomarker) — PMID 24735548

pubmed.ncbi.nlm.nih.gov · 2014

WADA-validated detection

View Study

Blackman MR, Sorkin JD, Münzer T, et al. 2002 — Growth Hormone and Sex Steroids in Healthy Older Adults (JAMA, PMID 12435261)

jamanetwork.com · 2002

Multi-center RCT

View Study

Rudman D, Feller AG, Nagraj HS, et al. 1990 — Effects of HGH in Men over 60 (NEJM, PMID 2355952)

nejm.org · 1990

Foundational anti-aging HGH trial

View Source

Molitch ME, Clemmons DR, Malozowski S, et al. 2011 — Endocrine Society Adult GHD Clinical Practice Guideline

ncbi.nlm.nih.gov · 2011

Diagnostic + treatment standard

View Source

FDA Genotropin (somatropin) Prescribing Information

accessdata.fda.gov

Reference somatropin label

View Source

FDA Skytrofa (lonapegsomatropin) Prescribing Information (2021)

accessdata.fda.gov · 2021

Long-acting weekly approval

View Source

21 USC § 333(e) — Federal Criminalization of Off-Label hGH Distribution

law.cornell.edu

Up to 5 years imprisonment for non-FDA-approved distribution

View Source

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…